Takeda Partners with Twist Bioscience to Expand Biologics Discovery Capabilities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
TAK Deal Validated Twist Bioscience's (TWST) Therapeutics Efforts - Cowen
July 8, 2020 1:02 PM EDTCowen analyst Doug Schenkel reiterated an Outperform rating Twist Bioscience (NASDAQ: TWST) after the company announced a partnership with Takeda to provide them access to its proprietary phage display libraries to develop novel biologics. TWST will receive an annual license fee and is eligible for... More
